Barclays PLC Buys 47,059 Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT)

Barclays PLC increased its stake in shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT) by 79.6% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 106,174 shares of the company’s stock after acquiring an additional 47,059 shares during the quarter. Barclays PLC owned approximately 0.08% of Nautilus Biotechnology worth $303,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. Dimensional Fund Advisors LP increased its holdings in shares of Nautilus Biotechnology by 19.8% during the second quarter. Dimensional Fund Advisors LP now owns 574,844 shares of the company’s stock valued at $1,345,000 after acquiring an additional 94,908 shares in the last quarter. MetLife Investment Management LLC acquired a new stake in Nautilus Biotechnology in the 3rd quarter valued at $87,000. The Manufacturers Life Insurance Company acquired a new stake in Nautilus Biotechnology in the 3rd quarter valued at $67,000. Wexford Capital LP increased its stake in Nautilus Biotechnology by 9.6% during the 3rd quarter. Wexford Capital LP now owns 228,350 shares of the company’s stock valued at $651,000 after purchasing an additional 20,000 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new position in Nautilus Biotechnology during the third quarter worth $50,000. 50.71% of the stock is currently owned by institutional investors and hedge funds.

Nautilus Biotechnology Trading Up 1.6 %

Shares of Nautilus Biotechnology stock opened at $1.93 on Tuesday. The company has a market capitalization of $242.33 million, a P/E ratio of -3.45 and a beta of 1.20. The stock has a fifty day simple moving average of $2.01 and a 200 day simple moving average of $2.42. Nautilus Biotechnology, Inc. has a 12-month low of $1.61 and a 12-month high of $3.12.

Nautilus Biotechnology (NASDAQ:NAUT) last posted its earnings results on Tuesday, October 29th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.17) by $0.04. During the same quarter in the prior year, the business posted ($0.13) earnings per share. On average, analysts predict that Nautilus Biotechnology, Inc. will post -0.57 EPS for the current year.

Analysts Set New Price Targets

Separately, The Goldman Sachs Group cut shares of Nautilus Biotechnology from a “neutral” rating to a “sell” rating and reduced their price objective for the company from $2.25 to $1.75 in a report on Thursday, December 5th.

Nautilus Biotechnology Profile

Nautilus Biotechnology, Inc, a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. The company develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis.